|
1000
|
Abstract/Summary
|
-
Dorothee von Laer and her team are investigating heterologous SARS-CoV-2 vaccination with Vaxzevria (AstraZeneca) and Comirnaty (BioNTech). The trial was started in May 2021 and is planned to be completed by the end of the year. The main goal is to analyze the safety and efficacy of the heterologous vaccination with Vaxzevria followed by Comirnaty. Participants are enrolled in three study arms with 1000 individuals each (aged 18-65) and receive either 2x Comirnaty 3-6 weeks apart, 2x Vaxzevria 11-13 weeks apart, or Vaxzevria followed by Comirnaty 11-13 weeks apart. Primary outcome measures are neutralizing antibodies, T cell response and vaccine failures. During this webinar, Dorothee von Laer will present first data and results. Dorothee von Laer is a German physician and virologist and has been a professor at the department of virology at the Medical University of Innsbruck since 2010.
|
